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Chapter 1
Precursor-directed Biosynthesis
Over the past 30 years natural products have contributed immensely to the
discovery of new drugs. Of the 1184 new medicinal chemical entities reported from
1981-2006, 70% have been based on natural products, and over 60% of all available
anticancer drugs since the 1940s are naturally derived.1 In the approach to new drug
discovery the development of high throughput screens has increased the demand for vast
libraries of compounds. These libraries often contain a random assortment of synthetic
compounds that are screened for binding to a target. This approach to drug discovery is
kind of like playing the lottery. A new approach focused on small libraries that resemble
natural products may actually be more beneficial. This is because naturally inspired
drugs greatly outnumber synthetic discoveries in many important areas of medicine, such
as cancer treatment (Figure 1.1). Nevertheless, libraries of natural product analogues
remain scarce because these complex molecules can be overwhelmingly challenging to
synthesize. In this regard precursor-directed biosynthesis (PDB) and mutasynthesis
(MBS) are gaining popularity as novel ways to generate complex natural product
analogues.1-5
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Figure 1.1: All available anticancer drugs, 1940’s - 2006 (N = 175). The naturally inspired categories include N –
Natural, ND - Naturally derived, S/NM – Synthetic natural product mimic, S* - Synthetic, natural product is/was
pharmacaphore , and S*/NM - Synthetic natural product mimic based on natural product pharmacaphore. (This
figure was reproduced without permission from: Newman, D. J; Cragg, G. M. J. Nat. Prod. 2007, 70, 461-467.)

Precursor directed biosynthesis and mutasynthesis encompass the same principle, which
is to use nature’s machinery to produce “non-natural” natural products (Figure 1.2).2 While
natural products constitute an important role in drug discovery, the derivatives of these
compounds are often more effective and exhibit fewer side-effects. The most basic example of
this is the conversion of salicylic acid into aspirin. One challenge in drug design is synthesizing
analogues of complex natural products that resemble medicinal leads. This is because natural
products often contain a large number of stereogenic centers and hetero atoms. While the total
synthesis of natural products continues to be challenging in the lab, plants possess the
indispensable enzymes to produce these products on demand.
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Figure 1.2: Precursor-directed Biosynthesis (PDB) and Mutasynthesis (MBS).2 (a) The wild type cell
assembles a secondary metabolite from primary precursors. (b) A mutant cell no longer expresses the gene coding
for the enzyme that generates one of the primary precursors. The secondary metabolite is no longer produced. (c)
Precursor-directed biosynthesis: A cell is supplemented with a precursor analogue in order to produce both a natural
product and a natural product analogue. (d) MBS: A cell is supplemented with a precursor analogue in order to only
produce a natural product analogue.

PDB and MBS provide the opportunity to assemble complex natural products that
wouldn’t otherwise be accessible. MBS was recently used to generate variants of the polyketide
anti-cancer compounds rapamycin and borrelidin (Figure 1.3).2 These compounds are both
isolated from bacteria of the Steptomyces genus and are structurally challenging to synthesize.
Using MBS seven novel rapamycin analogues and six novel borrelidin analogues were
synthesized and isolated, one of which shows a decrease in cytotoxicity when compared to
borrelidin. Further advances in MBS include introducing external genes into the biosynthetic
pathway of secondary metabolites.3 The halogenase gene prnA was introduced into
Streptomyces coeruleorubis which resulted in efficient in situ chlorination of the uridyl peptide
antibiotic pacidamycin. The chlorinated pacidamycin analogue was then functionalized using
mild cross-coupling to yield a number of post biosynthetic derivatives that were previously
inaccessible (Figure 1.4). This research exploits the potential of chlorine as a modification
handle on natural product analogues.
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Figure 1.3: Natural Product Analogues of Potential Anit-Cancer Drugs Rapamycin and Borrelidin. (This
figure was reproduced without permission from: Weissman, K. J. Trends Biotechnol. 2007, 25, 139-142.)

Figure 1.4:Chlorine as a Synthetic Handle. The bacteria S. coeruleorubidus was genetically engineered to
produce the non-natural, natural product chloropacidamycin which was further modified by a cross-coupling
reaction. (This figure was reproduced without permission from: Goss, J. M. R; Roy, A. D; Gruschow, S. and Cairns,
N. J. Am. Chem. Soc. 2010. 132, 12243-12245.)
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Although MBS has been implemented in bacteria biosynthesis for over 40 years, the
technique has not been fully explored in complex lengthy plant pathways. Recent evidence,
however, has shown that MBS can also be used to generate natural product analogues in
eukaryotic cells. The suppression of tryptamine biosynthesis in Catharanthus roseus cells
resulted in a viable hairy root culture that no longer produced monoterpene indole alakloids, their
natural secondary metabolites.4 However, when supplemented with fluorinated tryptamine
analogues C. roseus produced multiple fluorinated monoterpene indole alkaloids (Figure 1.5).
In a separate project a halogenase was engineered into C. roseus in order to biosynthetically
produce site selective chlorinated and brominated tryptamine analogues.5 These halogenated
precursors were generated in vivo and then accepted into the plants enzymatic pathway to
produce halogenated monoterpene indole alkaloid analogues. This evidence shows that MBS
provides a feasible method of using plants to synthesize natural product analogues in complex
eukaryotic cells.
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Figure 1.5: Natural Product Analogues Produced in Eukaryotic Cells. RNA silencing was used to prevent
production of the natural primary metaboltite tryptamine. Natural product analogues were produced upon the
addition of the primary metabolite analogue fluoro-tryptamine. (This figure was reproduced without permission
from: Maresh, J. M; O’Connor S. E; Runguphan, W. Proc. Natl. Acad. Sci. USA. 2009. 106, 13673-13678.)

PDB involves a much simpler approach than MBS in that no genetic engineering is
required. The purpose of PDB is often to establish that a specific enzymatic pathway is flexible
enough to produce evidence that an unnatural precursor has been accepted. Once proof of
natural product analogues has been established, metabolic engineering can be used to increase
yields and diversify precursor selectivity. In this sense PBD can be thought of as pioneering the
way for MBS.
The first step in PDB is to select an organism and secondary metabolite targets. The
organism Berberis vulgaris L., which produces an array of alkaloids6,7 including berberine,
palmatine and oxyacanthine, was chosen for this project. B. vulgaris is a promising organism to
work with because cell cultures are readily available from the DSMZ (German Collection of
Microorganisms and Cell Cultures) and not only is it known to produce large amounts of berberine,
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but the enzymatic pathway to the production of berberine is well established (Figure 1.6). A
well established metabolic pathway can prove useful in identifying enzymes that are not flexible
enough to handle unnatural analogues; as is evident by the build-up of intermediates. For
example, if HPLC-MS analysis showed a large amount of halogenated (S)-reticuline, the BBE
(berberine bridge enzyme) may not be flexible enough to accept halogenated (S)-reticuline.

Figure 1.6: The Metabolic Pathway of Berberine Synthesis. The primary metabolites dopamine and 4HPAA
undergo a series of enzyme catalyzed reactions which ultimately generate the secondary metabolite berberine.

The primary metabolite precursors of many alkaloids that B. vulgaris produces are
dopamine and 4-hydroxyphenylacetaldehyde (4HPAA). Dopamine and 4-HPAA are also
primary metabolites used in the production of alkaloids in many related species (Figure 1.9). In
this regard, fluorinated dopamine analogues were chosen as target precursor analogues for the
production of fluorinated berberine (Figure 1.7), as well as any other alkaloids produced by B.
vulgaris. The use of fluorine in PDB has many benefits. Fluorine can help identify products by
its signature +19 m/z in mass spectrometry and its unique NMR activity.8 Fluorine is relatively
small (when compared to chlorine and bromine) which may make it more likely to be accepted
by enzymes in metabolic pathways. Finally fluorine exhibits molecular properties that have
proven to be pharmalogically useful, as is evident by the fact that fluorine is present in 15% of
approved drugs.8 The medicinal use of fluorine in drugs can be broken down both
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pharmacokinetically and pharmacodynamically. Kinetically the fluorine-carbon bond is strong
which increases the half-life of drugs. This can decrease the dose and frequency of drug use.
Dynamically fluorine has electronic effects that alter a drugs interaction with target enzymes.
This effect can result in more successful drugs

Figure 1.7: Dopamine Analogues as Target Precursors. If accepted by the plant, dopamine analogues 5fluorodopamine (R2=F, R1=H) and 2-fluorodopamine (R1=F, R2=H) will combine with 4HPAA to produce
fluorinated berberine analogues.

The synthesis of fluorinated dopamamine has been reported in the literature.9 The
reported synthetic approach from Kirk incorporates the use of the Balz-Schiemann reaction and a
high pressure catalytic hydrogenation. After repeated failed attempts of reproducing these
methods, a new scheme was devised. The new approach can be broken down into two pathways,
both of which proceed through a fluorinated vanillin intermediate (Figure 1.8). In pathway 1, 3fluoroanisole is converted to 2-fluoroisovanillin10 (3) which is then used to synthesize 2fluorodopamine (6). In pathway 2, 3-fluoroanisole is converted to 5-fluorovanillin10 (9) which is
used to synthesize 5-fluorodopamine (12). Chapter 2 describes the chemistry used to synthesize
the vanillin intermediates, and the chemistry used to convert the vanillin intermediates to
dopamine analogues is highlighted in chapter 3.
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Figure 1.8: Synthesis of Fluorinated Dopamine Analogues. In pathway 1, 3-fluoroanisole is converted to 2fluoroisovanillin (3) which is then used to synthesize 2-fluorodopamine (6). In pathway 2, 3-fluoroanisole is
converted to 5-fluorovanillin (9) which is used to synthesize 5-fluorodopamine (12).

Dopamine represents an opportunistic primary metabolite because it is used by diverse
families of plants to generate many secondary metabolites (Fig 1.9). The chemistry used to
convert vanillin to dopamine provides a chemist with an arsenal of potential primary metabolite
analogues. These analogues, in theory, can be used to generate a variety of natural product
analogues that could serve a better medicinal purpose than their natural product counterparts.

Figure 1.9: Alkaloids Constructed with Dopamine and 4-Hydroxyphenelacetaldehyde (4HPAA). The primary
metabolites dopamine and 4HPAA are used by a variety of organisms to produce a range of different alkaloids.
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Chapter 2
Fluorinated Vanillin Analogues
Compounds 3 (2-fluoroisovanillin) and 9 (5-fluorovanillin) (Figure 2.1) were chosen as
precursors for 2-fluorodopamine (6, R1=F, R2=H) and 5-fluorodopamine (12, R1=H, R2=F). The
first attempt at synthesizing these fluorinated vanillin analogues incorporated the use of the BalzSchiemann reaction.11 The Balz-Schiemann reaction (Figure 2.2) involves the conversion of an
aniline to an aryl fluoride via a diazonium tetrafluoroborate intermediate. The availability of 2aminovanillin and the literature9 precedent for its conversion to 2-fluorovanillin made this
approach appear convenient.

Figure 2.1: Target fluorinated vanillin isomers. Compound 3; 2-fluoro-3-hydroxy-4-methoxybenzaldehyde (2fluoroisovanillin). Compound 9; 3-methoxy-4-hydroxy-5-fluorobenzaldehyde (5-fluorovanillin).

The conversion of aniline to fluorobenzene (reaction A, Figure 2.2) was attempted in
order to test its viability and become familiar with the Balz-Schiemann reaction. When
following the experimental procedure of A, the conversion of aniline to the diazonium
tetrafluoroborate salt went smoothly; however, the subsequent reaction of the salt was not as
easily accomplished. These results were expected, as the diazonium salt is a very reactive
intermediate. GC-MS analysis of the reaction A product suggested a product mixture of
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fluorobenzene and phenylhydrazine. While GC-MS analysis was optimistic, the product itself
was an oily tar that was difficult to handle. Due to the volatility of fluorobenzene and phenol
(another likely side-product), and in order to test an aromatic compound with ring substituents,
dimethyl analine was chosen as a better suited test reaction.

Reaction
A
B
C

Compound
Analine
2,6-dimethylanaline
2-aminovanillin

R1
H
CH3
OCH3

R2
H
H
OH

R3
H
CH3
COH

Figure 2.2: Balz-Schiemann Reaction Schemes. Three compounds, analine, 2,6-dimethylanaline, and 2aminovanillin, were used to test the Balz-Schiemann reaction.

Reaction B was carried out in a similar fashion as A and once again the diazonium salt
was easily isolated. The decomposition product of B was not purified, but GC-MS analysis
showed that 2,6-dimethylfluorobenzene was the major product. The results of reactions A and B
suggested that the diazonium salt could be generated in high yield, but that the decomposition
step would need optimization. The decision was made to forgo optimizing the test reactions and
to attempt reaction C.
Reaction C was attempted three times with minimal success. The desired product was
neither verified nor isolated. One major synthetic problem encountered was that the literature
reference used a “home-made” apparatus to pyrolyze the diazonium salt by irradiation.9 This
apparatus was not available for the present work. In order to overcome this issue, two distinctive
procedural changes were made. The first change was that NOBF4 was used in place of aqueous
NaNO2 and HBF4. This was done in an attempt to exclude water from the reaction. As a result
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of generating the aryl cation, water can react competitively with fluorine during decomposition
to generate phenols instead of fluorinated compounds. The second procedural change was that
the diazonium salt was decomposed in xylene in order to control the temperature during
decomposition. This was done because there is an increased risk of side products if the
diazonium salt decomposes too aggressively. After three attempts of reaction 3 failing to
indicate any sign of the desired product, a new synthetic approach was devised.
The second approach to fluorinated vanillin analogues is based on 3-fluoroanisole (1) as
the starting compound (Figure 2.3). This starting compound is inexpensive and commercially
available, but more importantly it already contains a fluorine atom which obviates the difficulties
associated with uncontrollable (i.e. F2) direct fluorination. From 3-fluoroanisole (1), the desired
products 2-fluoro-isovanillin (3) and 5-fluorovanillin (9) were synthesized in 45% and 55%
yields’ respectively.

Figure 2.3: Direct Routes to Fluorinated Vanillin Analogues. Reaction conditions: (a) n-butyl lithium (-78oC),
B(OMe)3, AcOH (0oC), 30% H2O2, (b) refluxing HMTA in TFA, (c) 40% dimethylamine, 37% formaldehyde in
ethanol reflux, and (d) Iodomethane followed by HMTA reflux in acetic acid.

3-Fluoroanisole (1) was converted to 2 (80%) using n-butyllithium and B(OCH3)3 at 78oC followed by treatment with acetic acid and hydrogen peroxide at 0oC. This reaction was
100% selective for the desired position under the conditions chosen. This was confirmed by
comparing the 1H-NMR and 19F-NMR spectra of 2 to a standard purchased from Sigma Aldrich.
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The Duff reaction, which employs hexamethylenetetramine in refluxing trifluoroacetic
acid, was used to generate 3 (56%) from 2. This reaction was regioselective on the 1-5 mmol
scale, however, when scaled up (>50 mmol) the reaction lost regioselectivity. The presence of
two isomers was easily observed by different retention times on GC-MS and HPLC, however,
the formyl position of each product was difficult to assign by NMR. In order to correctly assign
the formyl position, the product of a small scale reaction producing only one isomer was
sublimed, re-crystallized, and the X-ray structure was determined (Figure 2.4). This crystal
structure verified GC-MS, UPLC, HNMR and FNMR spectra for 2-fluoroisovanillin (3). The
second major product was thought to be 5-fluorovanillin (9), a conclusion that was verified by
the more selective reaction scheme 2.
A synthetic route to 5-fluorovanillin (Figure 2.3) was necessary in order to confirm the
characterization of the second product from the Duff reaction on 2, and to establish a reliable
synthetic route to the desired fluorodopamine analogue 12. A regioselective reaction using
dimethylamine and formaldehyde in absolute ethanol generated the benzylamine 7 (95%) from 2.
Benzylamine 7 was converted to the quaternary amine 8 (100%) using methyl iodide. This was
done in order to generate a better leaving group for conversion to the aldehyde. Upon treatment
with hexamethylenetetramine in refluxing acetic acid the quaternary amine was converted to 5fluorovanillin 9 (72%). Spectral analysis of 9 confirmed that it was the other major product in
the treatment of 2 with hexamethylenetetramine in TFA.
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Figure 2.4 X-ray Structure of 2-Fluoroisovanillin.

Table 2.2: Crystal and Structure Refinement Data for 2-fluoroisovanillin. The .res file is
included in appendix B.
Compound
Formula
Fw
space group
a, Ǻ
b, Ǻ
c, Ǻ
, deg
, deg
, deg
V, Ǻ3
Z
calc, g/cm-3
F000
(Mo K), mm-1
, Ǻ
temp, K
R; Rw
GOOF

2-Fluoroisovanillin
C8H7O3F
170.14
Pc
6.360(4)
6.857(4)
8.497(5)
90
98.169(19)
90
366.8(4)
2
1.604
1976
0.139
0.71073
300
0.0776; 0.1729
1.059
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The reactions starting with 3-fluoroanisole afforded the fluorinated vanillin analogues in
a much more reliable fashion than the Balz-Schiemann approach. While the Balz-Schiemann
reaction was untamable in the present work, one approach in the future may be to attempt the
decomposition step in a microwave reactor. The controlled input of energy in the form of
microwaves could excite the diazonium intermediate to the appropriate state for conversion to
the aryl fluoride. This would be a worthwhile endeavor because the best attribute of the BalzSchiemann approach is its selectivity. One drawback of the hexamethylenetetramine approach is
the unpredictability when formylating 2 directly. Each attempt yielded the products in different
proportions and large scale reactions gave poor yields. A convenient method using prep-HPLC
is currently being developed in order to separate the regio-isomers of fluorinated vanillin,
however this does not resolve the issue of low yields on large scale reactions. An interesting
project would be to tailor the reaction conditions to selectively produce each isomer in high
yield.
The versatility of the fluorovanillin products is two-fold. First, it can be used to
synthesize fluorinated dopamine analogues for the incorporation into the berberine pathway.
The synthetic pathway to fluorinated dopamine analogues is discussed in the chapter 3 and the
preliminary feeding experiments are described in chapter 4. The secondary purpose of
fluorovanillin is to be converted into fluorinated protocatechauldehyde analogues for
incorporation into the galanthamine pathway. The galanthamine project is further elucidated in
chapter 5.
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Chapter 3
Fluorinated Dopamine Analogues
5-Fluorodopamine (12) was synthesized from 5-fluorovanillin (9) in 79% yield (Figure
3.1). While this scheme may seem straightforward, no available* route to the synthesis of 12
had been previously reported in the literature. The greatest challenge encountered in this scheme
was working with and isolating the charged products of the amine reductions; the pKa values for
the amine and phenol are within ~1 unit making extractions into organic solvents challenging
and impractical. In an attempt to synthesize 12 a variety of reducing agents were used in
combination with protective and de-protective chemistry. This chapter outlines the various
approaches that resulted in the selected pathway.

Figure 3.1: Synthetic Scheme for 5-Fluorodopamine. 5-fluorovanillin (9) was converted into 5-fluorodopamine
(12) in three steps.9,12,13 Reaction conditions: (a) nitromethane and ammonium acetate in acetic acid reflux, (b) Pd/C
HCl under atmospheric H2, and (c) concentrated HBr reflux.

The condensation reaction of vanillin and nitromethane in refluxing acetic acid has been
extensively reported in the literature.12 This reaction was carried out on large scale (50 mmol,
72% re-crystallized yield) in order to generate material for test reactions. The condensation
reaction that generated 10 was optimized to 97% crude yield. The fluorinated compounds
required ~2x as long of reflux to go to completion and ethyl acetate was found to be the best
solvent for extraction.

*The only previously reported synthesis of 12 required a high pressure (40 psi) catalytic hydrogenation step.
The required reaction conditions were not reproducible, so a new scheme had to be developed.
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The previously reported synthesis of 12 involved reducing the alkene using sodium
borohydride and the nitro group was reduced under high pressure H2 over a platinum oxide
catalyst.8 This procedure was attempted, but no pure product was isolated. The alkene was
easily reduced using sodium borohydride (90%), however, the reduction of the nitro group at
atmospheric pressure using platinum oxide resulted in numerous side products and an
unrecoverable desired product. The failure of this reaction is probably two-fold. The obvious
problem is that the reducing pressure of H2 was not achieved (no high pressure hydrogenator was
available for use) and the secondary concern is that the phenol (11) was protected (with a
secondary methyl group) in the reported synthesis. Due to the fact that methylating the phenol
would not guarantee success, alternative means of reduction were explored.
Catalytic hydrogenation was originally ruled out because limited success was observed
with PtO2/C, Pt/C, and Rainey-nickel catalysts. HPLC analysis of product from these metal
catalysts revealed numerous side products and unreacted starting material. The first major lead
was observed when Zn dust in methanol with concentrated HCl resulted in complete conversion
of 4 to one product by HPLC. The product obtained was an oil which displayed the predicted
1

H- NMR peaks for the desired product, but also had an un-identifiable multiplet at δ 7.11 ppm

(Figure 3.2). The desired product could not be easily separated from the product resulting in the
multiplet because both were aqueous soluble and organic insoluble. The side product was
thought to some sort of Zn complex. The procedure to remove Zn from the reaction involved
making the solution slightly basic after the reaction. This was done because ZnCl42+ (product at
low pH) is soluble and Zn(OH)42- (product at high pH) is also soluble, but Zn(OH)2 (product at
intermediate pH) is insoluble in aqueous solution. This approach was attempted using both
NaOH and NH4OH, but in both cases the product still could not be isolated. In another
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procedure Na2CO3 was added in an attempt to precipitate ZnCO3, but this also failed to yield a
purified product. H2S was also used in an attempt to precipitate the insoluble compound ZnS. In
a final attempt column chromatography was used in four approaches where both silica and
alumina under acidic and basic work-up were implemented. After these columns failed to result
in a purified product, a new approach using protective group chemistry was devised.

Figure 3.2 : 1H NMR Displaying Side Product 3-Peak. The product 5 of the zinc reduction was difficult to purify
and exhibited an unidentifiable multiplet at 7.11 Hz.

Protective group chemistry was used in an attempt to make the reduction product soluble
(extractable) in organic solvent. The phenol of vanillin was protected with a benzyl group.14
The benzyl group was chosen because high yields were previously reported for benzylating
vanillin (as opposed to methylating) and the large hydrophobic group would likely increase
organic solubility (Figure 3.3). The synthesis of benzyl vanillin 20 was easily accomplished
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(91%), and the nitro-aldol condensation to produce 21 was also relatively high yield (93%). The
zinc catalyzed reduction of 21 did not go as smoothly as anticipated. The reduction was
attempted five times, but 22 was never isolated. The analysis of the product by HPLC showed
multiple peaks, so the success of the reaction remained in question. After the desired product
could not be extracted with either ether or dichloromethane, the protective approach was put on
hold. In the future, another solvent might be better for extraction such as ethyl acetate or
benzene, however, the actual success of the reduction remains in question.

Figure 3.3: Benzyl Protection Scheme. The phenol of vanillin was protected with a benzyl group in an attempt to
generate the phenol protected amine 22. Reaction conditions: (a) benzyl chloride, KI and NaHCO3 in acetonitrile,
(b) nitromethane and ammonium acetate in acetic acid reflux, and (c) Zn/HCl in methanol (unsuccessful).

Consultation of the literature turned up a reference in which nitrovinyl groups were
reduced to ethanamines using Pd/C with concentrated HCl and H2 at atmospheric pressure.13
After a successful test reaction, this method proved to be worth pursuing. A method was
developed in which 10 was reduced to 11 (90%) overnight at 1oC. An unexpected observation of
the 3-peak multiplet (Figure 3.2) was encountered in the 1H-NMR spectrum of this product.
Interestingly a wash with acetonitrile removed the byproduct at the cost of 10-20% of the yield.
The filtrate containing the byproduct was not analyzed further. This reduction has yet to be used
on the 4 because this isomer has to be isolated or synthesized. A method is currently being
developed to separate the nitrovynl compounds 4 and 10 by prep-HPLC.
The final step in the synthesis of dopamine analogues from vanillin involves demethylating 11. The demethylating methods tested were HBr and AlCl3.9 The AlCl3 method
was ideal for reactions in which the desired product was organic soluble and could be extracted
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from the aqueous reaction mixture. This reaction was found to be successful in de-protecting
vanillin and vanillin nitrostyrene. However, the de-protected catechol nitrovynl product was not
easily reduced. The second method, reflux in concentrated HBr, worked well only under specific
conditions. The product of the reaction, dopamine, is a catechol and under the harsh reaction
conditions can decompose to benzoquinone and subsequently polymerize via Diels Alder
reactions or Michael addition (Figure 3.4).14 In order to prevent the oxidation and
decomposition of the dopamine as it formed, H2 gas was bubbled through the refluxing reaction.
5-Fluorodopamine was synthesized in 90% to quantitative yields using this method.

Figure 3.4: The decomposition of Catechols. When exposed to oxygen catrechols auto-oxidize to benzoquinones.
This process is facilitated by an aqueous environment. The benzoquinone is a reactive intermediate that can easily
polymerize.

The crystal structure of 5-Fluorodopamine was solved (Figure 3.5). 5-Fluorodopamine
crystallized in the P21/C space group with a maximum resolution 0.84 Å. The extended structure
was made up of layers of hydrophobic ring stacking interactions and hydrogen bonding networks
between the amine, phenols, and the bromide ion. In combination with 1H-NMR, 19F-NMR and
13

C-NMR, this crystal structure provided proof of structure for the final product.
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Figure 3.5: The crystal Structure of 5-Fluorodopamine.

Table 3.1: Crystal and Structure Refinement Data for 5-fluorodopamine. The .res file is
included in appendix B.
Compound
Formula
Fw
space group
a, Ǻ
b, Ǻ
c, Ǻ
, deg
, deg
, deg
V, Ǻ3
Z
calc, g/cm-3
F000
(Mo K), mm-1
, Ǻ
temp, K
R; Rw
GOOF

5-Fluorodopamine
C8H6BrFNO2
252
P21/C
10.822 (3)
12.884 (3)
6.845 (2)
90
92.384 (10)
90
953.5 (5)
4
1.721
484
0.139
0.71073
300
0.092; 0.258
1.05
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Chapter 4
Feeding Experiments and Initial Results
The first step in setting up feeding experiments was to pick an ideal organism. For the
purposes of this project, a producer of the alkaloid berberine was targeted. The organism chosen
was Berberis stenophyllia from the Berberidaceae family. This species is a known producer of
Berberine as well as a well documented trove of other alkaloids. A cell culture of Berberis
stenophyllia was purchased from Deutche Sammlung von Mikro-organismen und Zellkulturen
(DSMZ) and these cell cultures are continuously re-plated in-house on LS media. A typical
feeding experiment involves transferring cells from a plated cell culture to a liquid media in
which the precursor compound is dissolved. Another feeding option is to pre-cultivate friable
cell cultures in liquid media. Friable cell cultures consist of numerous small cell colonies that
posses increased surface area as opposed to plate colonies which tend to be large and globular.
Upon completing the synthesis of 5-fluorodopamine (12), initial feeding experiments were set
underway.
The first feeding experiment was designed as a test reaction to see how the cells would
respond to an environment of exogenous 5-fluorodopamine. The contents of one plate of cell
culture was transferred to a sterilized 1 L Erlenmeyer flask which was filled with 100 mL of
liquid LS media supplemented with 1.0 mM 5-fluorodopamine. After three days of incubation,
the media had become visibly darkened. The results were not ideal as it was thought that the
fluorinated dopamine had oxidized and polymerized after being dissolved in the media (Figure
3.4). In order to test this hypothesis, a sample of 5-fluorodopamine was incubated with liquid LS
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media and a black substance precipitated overnight. In order to give the cells a chance to absorb
the precursor, a new strategy had to be developed.
A procedure to acetylate the phenols in order to prevent the auto-decomposition of
dopamine analogues is currently being developed (Figure 4.1). Acetylation of the phenols was
chosen as an ideal protective group because plant cells contain a large number of deacetylating
enzymes. In theory, the plant should absorb the acetylated precursor and deacetylate it in vivo.
Both phenols of dopamine were selectively acetlyated (avoiding acetylation of the amine) using
acetyl chloride in trifluoroacetic acid to produce diacetyl dopamine in 60% yield.15 An
experiment comparing the tendency of acetyl dopamine and dopamine to decompose was
conducted. The rate of decomposition of acetylated dopamine visually appeared to be much
slower. In comparison to dopamine the half life of acetyl dopamine is estimated to be roughly 25 times as long. This amount of time will hopefully be long enough for the culture to absorb the
precursor before it oxidizes. The next steps in this project are to acetylate the fluorinated
dopamine analogues, as well as examine the first feeding experiment to determine if any 5fluorodopamine was incorporated into alkaloid synthesis before it decomposed.

Figure 4.1: Auto-Decomposition of Dopamine. After 24 hrs dopamine visibly polymerizes in liquid LS media
(A), however, acetylated dopamine remains unchanged (B).
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UPLC-MSMS is needed in order to analyze the cell extracts for natural product
analogues. Our research group is currently working on collaborating with the University of
Illinois, Chicago in order use their instruments for analysis of our cellular extracts. In the mean
time the cellular extracts containing alkaloids can be frozen for preservation.
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Chapter 5
Galanthamine Project

Figure 5.1: Galanthamine

Galantamine (GAL; Figure 5.1) is an alkaloid found in the bulbs and flowers of the
common snowdrop and several other members of the Amaryllidaceae family. The structure is
composed of four ring systems that form a rigid structure with minimal conformational mobility.
In the early 1950s the extracted compound was used to treat nerve pain and was later found to be
useful in treating many other ailments including facial nerve paralysis and schizophrenia.17 The
therapeutic effects of GAL are thought to be derived from its interaction with
acetylcholinesterases (AChEs) and nicotinic acetylcholine receptors (nAChRs).16-19 GAL binds
AChE in human erythrocytes with an IC50 of 0.35 µM and neuronal AChE at a 10-fold lower
potency.16 GAL also sensitizes nAChRs of muscles and the brain. After FDA approval, the
hydrobromide salt of GAL became marketed under the name Razadyne® ER as a prescription
treatment for the symptoms of Alzheimer’s disease (AD). GAL is currently being tested in
clinical trials for the treatment of schizophrenia, Parkinson’s Disease, and other neurological
disorders. Clinical trials exhibit a minor improvement for treating the symptoms of AD, but
GAL has not been proven to cure the underlying causes of AD.
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The crystal structure of GAL bound to Torpedo californica acetylcholinesterase
(TcAChE) has been reported.16 GAL binds to this receptor with an IC50 of 0.652 µM. The
relatively tight binding of GAL to TcAChE (Figure 5.2) is reversible and does not include any
covalent linkage. GAL is not a transition state analogue, however, it does block the active site
pocket and catalytic residues. The crystal structure shows that that GAL interacts with TcAChE
via two hydrogen bond moieties and numerous hydrophobic interactions. The hydroxyl group of
GAL forms a hydrogen bond with the carboxylic acid of Glu199 and the o-methoxy group of the
phenyl ring acts as a hydrogen bond acceptor for the hydroxyl group on Ser200. The most
prominent hydrophobic interactions seem to arise from pi-stacking interactions of the inhibitor
with Phe288, Phe330, Phe331, and Trp84. The rigid geometry of the inhibitor ring systems
allows GAL to conveniently fit in the active site pocket without the need to bind to the enzyme.
Thus, the tertiary amine of GAL does not covalently interact with the catalytic residue that bind
the amine of choline (Trp84), but rather blocks access to these sites.

Figure 5.2: Galanthamine and Acetylcholinesterase Crystal Structure. Galanthamine bound in the active site
pocket of Torpedo californica acetylcholinesterase (TcAChE).
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Galanthamine represents an interesting target compound for PDB because of its well
documented medicinal pharmacology.16-19 The resolved crystal structure of bound GAL
provides a platform to generate hypotheses about the pharmalogical activity of analogues. For
example, a galanthamine analogue fluorinated at either X or Y (Figure 5.3) would have an
altered hydrogen bonding network with the active site of its target enzyme. The two precursor
metabolites for the biosynthesis of galanthamine are tyramine and protocatechauldehyde PCA
(Figure 5.4). A chemical library of these analogues could potentially generate 100s of different
galanthamine analogues. These analogues would have significantly different properties than
galanthamine and could potentially be better drug candidates.

Figure 5.3: Primary Metabolites for the Biosynthesis of Galanthamine. PCA and Tyramine analogues can be
used to generate natural product analogues of galanthamine.

The synthesis of fluorinated PCA and tyramine analogues is currently underway. The
tyramine analogue 3-fluorotyramine (15) was synthesized from tyramine in 1 step using
selectflour in 38% yield. The fluorinated product, however, remains as a mixture with some unreacted tyramine. A prep-HPLC method is currently being developed in order to isolate pure 5fluorotyramine. The PCA analogue 2-fluoro-3,4-dihydroxy benzaldehyde (23) can be easily
generated in one step from 5-fluorovanillin. This reaction has not yet been performed because
the product, a catechol, is sensitive to auto-oxidation. The product will be synthesized when
daffodil cell cultures are cultivated.
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Figure 5.4: Analogue Precursor Targets for Galanthamine Project. Compound 23; The PCA analogue 2-fluoro3,4-dihydroxy benzaldehyde. Compound 15; The tyramine analogue 3-fluorotyramine.

In order to initiate PDB experiments viable cell cultures need to be cultivated. Our group
has been attempting to generate these cultures for the previous six months with little success.
Upon completing the synthesis of precursor analogues for this project, a new focus will be to
generate viable culture. The daffodil bulb extracts show that the species our group is working
with produce large amounts of galanthamine. The most promising aspect of galanthamine
project is that the secondary metabolites can be analyzed in-house by GC-MS (Figure 5.5).

Figure 5.5: Galanthamine GC-MS. The mass spectrum on the left is daffodil bulb extract and the mass spectrum
on the right is a galanthamine standard.
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Chapter 6
Synthetic Procedures
Methods. All reagents used were purchased from Sigma-Aldrich. GC-MS analysis was
performed using a Hewlett Packard HP6890 GC System with an Agilent Technologies 5975 inert
mass selective detector. HPLC analysis was performed using a Waters Aquity Ultra
Performance liquid chromatography instrument equipped with an Aquity UPLC BEH C18 (1.7
µm) 2.1x100 mm column. Using a Bruker Avance 300 MHz instrument 1H-NMR, 13C-NMR
and 19F-NMR spectra were acquired at 300 MHz, 100 MHz and 282 MHz respectively. 1HNMR chemical shifts and 13C-NMR chemical shifts are relative to (CH3)4Si, and 19F-NMR
chemical shifts are referenced to an internal standard of CFCl3.
O

O
HO
F
1

F
2

2-Fluoro-6-methoxyphenol (2). 4.0 mL (9.4 mmol) of 2.36 M n-butyl lithium was added
dropwise over 1 hr to a solution of 1.28 g (10 mmol) fluoroanisole (1) in 10.0 mL dry THF kept
below -65 oC by a dry ice/acetone bath. The solution was stirred for 2 hrs at -78 oC under
nitrogen. 1.17 g (11 mmol) B(OMe)3 in 2.00 mL dry THF was added dropwise over 1 hr at -78
o

C and the solution was stirred for an additional 0.5 hr at -78 oC. The solution was warmed to 0

o

C and 0.88 mL (15 mmol) AcOH was added followed by the dropwise addition of 1 mL (10

mmol) of 30% H2O2. The solution was stirred overnight at 25 oC. The solution was diluted with
H2O (10 mL) and extracted with THF ( 2 X 10 mL). The combined ether extracts were washed
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with H2O ( 2 X 6.66 mL) and 10% Mohrs salt (2 X 3.33 mL). The ether phase was dried with
MgSO4 and evaporated under reduced pressure to yield 1.16 g (2) (80%). Reaction scale,
(yield): 174 mmol, (63%); 261 mmol, (80%). 1H NMR (300 MHz, CDCL3 ) δ 6.82 – 6.63 (m,
1H), 5.51 (s, 1H), 3.90 (s, 1H). 19F NMR (282 MHz, CDCl3) ppm -137.61 (m, 1F). GCMS-EI:
m+ 142, 127.
Observations/Notes
The nmr/gc/uplc suggest that the reaction was site specific adding solely at the specified
position. A good deal of product (roughly 20-30% was lost during vacuum distillation). This
was a result of ungreased joints and a relatively weak house vacuum. I believe that these losses
could be reduced if the experiment is repeated. A slower addition would also be beneficial;
however, the experiment already takes a long time. There was no way to cool the liquid being
added because it was in a syringe. If the n-butyl lithium could have been cooled before it was
added the yield may be improved.

Reference
Ladd, D. L.; Weinstock, J. J. Org. Chem. 1981, 46, 203.
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2-Fluoro-3-hydroxy-4-methoxybenzaldehyde (3). A solution of 0.500 g (3.5 mmol) 2-Fluoro6-methoxyphenol (2) in 5 mL trifluoroacetic acid was added dropwise over 1 hr to a refluxing
solution (80 oC) of 0.986 g (7.0 mmol) hexamethylenetetramine in 5 mL trifluoroacetic acid.
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The reaction was refluxed for 1 hr, allowed to cool to room temp and concentrated under
vacuum. 25 mL of ice water was added and the reaction was stirred for 15 min. The pH of the
reaction mixture was neutralized by the addition of solid potassium carbonate. The reaction
slurry was stirred for 20 min, extracted with ether ( 3 X 25 mL), washed with water (3 X 25),
dried with MgSO4 and evaporated under vacuum to yield 0.3378 g (56%) of 2-fluoro-3-hydroxy4-methoxybenzaldehyde (3). Scale, % yield: 3.5 mmol, 40%; 3.5 mmol, 34%; 56 mmol, 14%;
100 mmol, 28%. 1H NMR (300 MHz, DMSO) δ 10.03 (s, 1H), 9.65 (s, 1H), 7.32 (dd, J = 8.7,
7.5 Hz, 1H), 6.99 (dd, J = 8.8, 1.2 Hz, 1H), 3.91 (s, 2H).

19

F NMR (282 MHz, DMSO) δ -135.60

(ddd, J = 9.4, 2.3, 1.1 Hz). GCMS-EI: m+ 142; b.p. 127.

Observation/Notes
This reaction worked a lot better on a smaller scale. The small scale reaction resulted in
mainly one isomer while scaled up reactions resulted in formulation at all three positions (the
isomer with F para to the aldehyde was only ~1%) with differnet ratios each time. On a large
scale the desired isomer (3) ultmately became the minor product to 3-fluoro-4-hydroxy-5methoxybenzaldehyde (5) which was also a desired product. GCMS and UPLC showed that the
ratio between (3) and (5) was 40:60 on the largest scale reaction. The lower yield on larger scale
reactions may have resulted from an inability to remove trifluoroacetic acid which led to difficult
extraction. For an unknown reason the trifluoroacetic acid was very difficult to evaporate, even
with heat. The J coupling of 9.4 Hz for the fluorine was interesting because no proton exhibited
direct coupling of 9.4 Hz. This may be a result of the F NMR being aquired in D-acetone, or a
complex splitting system.

Reference
Clark, M. T.; Miller, D. D. J. Org. Chem. 1986, 51, 4072.
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(E)-2-fluoro-6-methoxy-3-(2-nitrovinyl)phenol (4). A reaction mixture of 0.800 g (4.7 mmol)
2-Fluoro-3-hydroxy-4-methoxybenzaldehyde (3), 1.44 g (24 mmol) nitromethane, 0.363 g (4.7
mmol) ammonium acetate, and 5.0 mL acetic acid was refluxed for 6 hours. After cooling, the
reaction mixture was diluted with water (15 mL) and extracted with ether (3 X 25 mL). The
combined ether extracts were washed with water (1 X 25 mL), dried with MgSO4, and
evaporated under reduced pressure. 0.65 g (65%) of (E)-2-fluoro-6-methoxy-3-(2nitrovinyl)phenol was collected without further purification. 1H NMR (300 MHz, DMSO) δ
9.68 (s, 1H), 8.02 (q, J = 13.7 Hz, 1H), 7.41 (t, J = 8.3 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 3.89 (s,
1H).

19

F NMR (282 MHz, DMSO) δ -134.04 (dd, J = 7.8, 1.6 Hz).

Observation/Notes
The fluorinated analog of vanillin requires much more time to react than vanillin. The
reflux should be done for at least 7 hours (or until complete by TLC). Ethyl acetate was also
found to be a much more effective solvent for extraction. The extraction process may require up
to 5 extractions with ethyl acetate. As long as the reaction goes to completion the only
impurities should be acetic acid and nitromethane. These impurities can be mostly washed away
and the product can be recrystallized from a 75:25 water/methanol solution.
References
J. Org. Chem., Vol. 41, No. 14, 2372 1976
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3-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrobromide (5). This compound will be made
using the same method as 4-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrochloride (11). The
starting compound needs to be isolated from an isomeric mixture with (E)-2-fluoro-6-methoxy4-(2-nitrovinyl)phenol (10).

3-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrobromide (2-Fluorodopamine) (6). This
compound will be made using the same method as 2-Fluoro-3,4-dihydroxyphenethylamine
Hydrobromide (5-Flurodopamine HBr) (12).

N,N-Dimethyl-3-hydroxy-4-methoxy-5-fluorobenzylamine (7). 2-Fluoro-6-methoxyphenol
13.0 g (91 mmol) was added to a solution of 19.5 g (160 mmol) 40% dimethylamine and 11.7
mL (160 mmol) 37% formaldehyde in 91 mL of absolute ethanol. The reaction mixture was
heated at reflux for 2 hours, cooled to room temperature, and concentrated under vacuum to a
white solid. The solid was triturated with ether to give 17.25 g (95%). Scale, % yield: 8.5
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mmol, 72%. 1H NMR (300 MHz, CDCl3) δ 6.67 (t, J = 4.6 Hz, 1H), 3.90 (s, 1H), 3.32 (s, 1H),
2.23 (s, 3H).

19

F NMR (282 MHz, CDCL3) δ -138.08 (dd, J = 11.1, 1.7 Hz).

Observation/Notes
This reaction can easily be scaled up with high yields. Also, the product does not need to
be purified before continuing with next step.
Reference
Ladd, D. L.; Weinstock, J. J. Org. Chem. 1981, 46, 203.

1-(3-fluoro-4-hydroxy-5-methoxyphenyl)-N,N,N-trimethylmethanaminium iodide (8).
Iodomethane (170 mL) was added to a solution of N,N-Dimethyl-3-hydroxy-4-methoxy-5fluorobenzylamine 17.0 g (85 mmol) in CHCl3 (850 mL). The mixture was stirred overnight at
room temperature. The solution was filtered and an off-white solid was collected 25.6 g (78%).
Scale, % yield: 5 mmol, 100%. 1H NMR (300 MHz, DMSO) δ 9.78 (d, J = 1.8 Hz, 1H), 7.14 –
6.86 (m, 2H), 4.41 (d, J = 7.0 Hz, 2H), 3.85 (d, J = 2.7 Hz, 3H), 3.13 – 2.84 (m, 9H).
(282 MHz, DMSO) δ -135.24 (dd, J = 25.8, 10.4 Hz).
Reference
Ladd, D. L.; Weinstock, J. J. Org. Chem. 1981, 46, 203.

19

F NMR

35

3-Methoxy-4-hydroxy-5-fluorobenzaldehyde (9). A solution of (3-fluoro-4-hydroxy-5methoxyphenyl)-N,N,N-trimethylmethanaminium iodide 25.4 g (74 mmol) in acetic acid (65
mL) and H2O (65 mL) was heated to reflux. Hexamethylenetetramine 40 g (285 mmol) was
added to the refluxing solution in one portion. The mixture was stirred at reflux for 2 hrs and
then concentrated HCl (16.4 mL) was added. The solution was stirred an addition 5 minutes,
cooled, and extracted with ether (3 X 175 mL). The organic layer was washed with H2O (2 X
175 mL), dried with MgSO4 and concentrated under vacuum to give (9.00 g, 72%) of a white
powder. Scale, % yield: 5 mmol, 60%. 1H NMR (300 MHz, CDCl3) δ 9.75 (s, 1H), 7.35 (d, J =
10.3 Hz, 1H), 7.31 (s, 1H), 3.88 (s, 3H). 19F NMR (282 MHz, C6D6) δ -134.71 (d, J = 10.2 Hz).
Observation/Notes
The product of this reaction smelled like ammonia (or some other amine). The product
can be purified by sublimation or should be dissolved in an organic solvent and washed with
water until amines are no longer present.
Reference
Ladd, D. L.; Weinstock, J. J. Org. Chem. 1981, 46, 203.

(E)-2-fluoro-6-methoxy-4-(2-nitrovinyl)phenol (10). A reaction mixture of 3-Methoxy-4hydroxy-5-fluorobenzaldehyde 2.55 g (15 mmol), nitromethane 4.58 g (75 mmol), ammonium
acetate 1.18 g (15 mmol), and acetic acid (15 mL) was refluxed for 7 hours under nitrogen.
After cooling the reaction mixture was diluted with water (30 mL) and extracted with ethyl
acetate (5 X 50 mL). The combined organic extracts were washed with water (3 X 75 mL), dried
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with MgSO4, and evaporated under reduced pressure. (E)-2-fluoro-6-methoxy-4-(2nitrovinyl)phenol 3.10 g (97%) was collected as a red powder without further purification. 1H
NMR (300 MHz, DMSO) δ 8.09 (dd, J = 45.6, 13.3 Hz, 2H), 7.41 (d, J = 11.6 Hz, 1H), 7.35 (s, J
= 11.8 Hz, 1H), 3.85 (s, 3H).

19

F NMR (282 MHz, DMSO) δ -135.35 (d, J = 11.5 Hz).

Observation/Notes
The reaction should be allowed ample time to complete as side products were generally
not formed and nearly quantitative yields of the product can be achieved. The extraction process
may require that the aqueous washed be re-extracted with ethyl acetate. As long as the reaction
goes to completion the only impurities should be ethyl acetate, acetic acid, and nitromethane.
These impurities can be mostly washed away and the product can be recrystallized from a 75:25
water/methanol solution. When a 50:50 water/methanol solution was used only 57% of the
product was collected. Due to limited solubility of the product in water, increasing the water
ratio during recrystalization was found to improve recovery.
References
J. Org. Chem., Vol. 41, No. 14, 2372 1976

4-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrochloride (11). A 25 mL round bottom
flask was charged with 200 mg 5% palladium on carbon, 1 mL concentrated HCl, and 10 mL
MeOH. The flask was sealed, placed in an ice bath and equilibrated under a hydrogen filled
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balloon for 30 minutes. E-2-fluoro-6-methoxy-4-(2-nitrovinyl)phenol (10) 0.213 g ( 1 mmol)
was added and the reaction mixture was stirred vigorously over night in a refrigerator (2o C)
under a hydrogen filled balloon. The next day the reaction was stirred under a new hydrogen
filled balloon for 5 hours at room temperature. The reaction mixture was then filtered through
celite and the celite (containing catalyst) was washed with 40 mL of additional methanol. The
methanol was evaporated under reduced pressure and the residue was dried overnight in a
vacuum desicator to yield 0.200 g (90%) (11) as an off white powder. 1H NMR (300 MHz,
DMSO) δ 9.06 (s, 1H), 7.89 (s, 3H), 6.69 (dd, J = 9.6, 1.9 Hz, 2H), 3.80 (s, 3H), 3.01 (s, 2H),
2.77 (t, J = 7.6 Hz, 2H).

19

F NMR (282 MHz, DMSO) δ -135.70 (d, J = 10.2 Hz).

Observation/Notes
The reaction was also completed using 2X the mass of 5% palladium on carbon catalyst.
This reaction should not produce any side products visualized by UPLC, however, a strange “3peak” is normally observed on the proton NMR with a chemical shift of 7.20 (t, J = 51.7 Hz).
This “3-peak” involves exchangeable protons (D2O) and can be removed by washing the product
with dried (MgSO4) ice-cold acetone and acetonitrile separately, followed by dry ether. The
reaction has been scaled up to 3 mmol, however, the yield was reduced to 50% after washings.
If the product is an oil, it can be dissolved in THF and re-crystalized by dripping into ether. The
resulting solid should be centrifuged in order to concentrate for collection. If the product has “3peak” impurities it will be hygroscopic and oil up during vacuum filtration. Also, it may be
helpful to sonicate the crude product of the reaction in acetonitrile, or a mixture of acetonitrile
and ether.
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Reference
Bull. Chem. Soc. Jpn., 63, 1252-1254 (1990)

2-fluoro-6-methoxy-4-(2-nitroethyl)phenol (13). Sodium borohydride, 0.210 g (5.6 mmol)
was dissolved in 7 mL of ethanol and cooled to 0o C under nitrogen. E-2-fluoro-6-methoxy-4-(2nitrovinyl)phenol (12), 0.570 g (2.5 mmol) was dissolved in 20 mL of ethanol and added
dropwise to the sodium borohydride solution over 1.66 hours. Following the addition, the
reaction mixture was stirred in a refrigerator for 26 hours. After storage, the solution was made
slightly acidic with 4 M HCl and diluted with H2O (20 mL). The solution was extracted with
ether (3 X 20 mL) and the organic phase was washed with brine (1 X 20 mL), dried with MgSO4,
and evaporated under reduced pressure to obtain ~1.0 g of oil. The oil was extracted with ether
(leaving behind a slightly orange solid) and evaporated under reduced pressure. The residue was
sonicated and extracted into toluene and the solvent was removed under reduced pressure to
yield 0.5359 g (99%) of an orange oil. The product was verified by UPLC.
Observation
The work-up of this reaction can be difficult when it comes to removing the borohydride salts,
which seem to be somewhat organic soluble. Toluene was used in order to extract product from
an impure mixture, however, any method that isolates product from borohydride salts should be
sufficient. Also, the product of this reaction and of test reactions involving non-halogenated
vanillin nitrostyrenes were generally oils.
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References
J. Org. Chem., Vol. 41, No. 14, 1976

2-Fluoro-3-hydroxy-4-methoxyphenethylamine hydrochloride (11). A 50 mL round bottom
flask was charged with 2-fluoro-6-methoxy-4-(2-nitroethyl)phenol (13) 0.536 g (2.5 mmol), 10%
Pt/C 0.125 g, and 20 mL of ethanol. The reaction mixture was stirred under a hydrogen balloon
for 3 days and then 0.125 g of 10% Pt/C was added and the reaction was stirred for an additional
day. The mixture was filtered through celite using an additional 20 mL of ethanol and 0.5 mL of
concentrated HBr was added to make solution acidic. The solvent was removed by vacuum and
a brown oil was collected. The oil was diluted with 10% Acetonitrile/Ether and sonicated to give
a white solid. The NMR results were inconclusive.
Observations/Notes
This reaction was monitored by UPLC and after 24 hrs the reaction appeared to be about
50% complete. Over the course of the next few days side products built up and the starting
material remained present. The NMR results suggest that the desired product was made,
however, the product was never separated from the other species present in the NMR so it
remains uncertain whether the final product contained two different compounds or one
compound that was a side product which formed during the reduction. This reaction was based
off a procedure in which a catalytic hydrogenator was used in order to generate a reducing
environment at 40 psi whereas this reaction proceeded at roughly 14.7 psi of H2.
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References
J. Org. Chem., Vol. 41, No. 14, 1976

2-Fluoro-3,4-dihydroxyphenethylamine Hydrobromide (5-Flurodopamine HBr) (12).
Hydrogen gas was bubbled through 13 mL of refluxing concentrated hydrobromic acid which
was closed off from the atmosphere. After 20 minutes, 2-Fluoro-3-hydroxy-4methoxyphenethylamine hydrochloride (11) 0.290 g (1.3 mmol) was added and the mixture was
refluxed for 3 hours while hydrogen gas was continually bubbled through. The excess
hydrobromic acid was removed by vacuum and the resulting product was dissolved in methanol
(15 mL) and evaporated to dryness under vacuum. This step was repeated again using methanol
(15 mL), followed by H2O (15 mL), and finally methanol (15 mL). After the final evaporation
the product was placed in a vacuum desicator overnight and 0.367 g (>100%) of the
hydrobromide salt was collected. 1H NMR (300 MHz, CDCl3) δ 7.87 (s, 5H), 6.52 (dd, J = 11.3,
2.0 Hz, 1H), 6.48 (d, J = 1.4 Hz, 1H), 3.02 – 2.90 (m, 2H), 2.74 – 2.62 (m, 2H).

13

C NMR (75

MHz, DMSO) δ 152.41 (d, J = 237.2 Hz), 148.10 (d, J = 6.3 Hz), 132.34 (d, J = 14.3 Hz),
127.92 (d, J = 8.8 Hz), 112.31 (s), 107.17 (d, J = 19.3 Hz), 40.43 (s), 32.74 (s).

19

F NMR (282

MHz, DMSO) δ -135.23 (dd, J = 11.2, 1.2 Hz).
Notes/Observations
The starting material for this reaction needs to be pure. The reaction mixture turns black if the
starting material is impure and the product is a black tar. The product can be purified by
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dissolving it in hot ethanol and adding ether as the solution cools. The best results were obtained
when the reaction was kept under a hydrogen atmosphere. For the best results an apparatus
should be created to bubble hydrogen through the refluxing reaction. The slow diffusion of ether
into isopropanol works well to re-crystallize the product.
References
J. Org. Chem., Vol. 41, No. 14, 1976

4-(aminomethyl)-2-fluorophenol hydrochloride (3-Fluorotyramine Hydrochloride) (15).
Tyramine Hydrochloride (4.00 g, 23 mmol) and selectfluor (1-Chloromethyl-4-fluoro-1,4diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)) (8.24 g, 23.2 mmol) were dissolved in 104
mL of 50/50 methanol:water and stirred at room temperature for 72 hrs. The solvent was
removed from the reaction mixture under vacuum, and the crude product was dissolved in 80 mL
methanol and filtered. The solvent was removed from the filtrate and the product was
precipitated from acetonitrile (40 mL) to give 1.61 grams (37%). UPLC, NMR, and GCMS
analysis showed a mixture of 3-Fluorotyramine hydrochloride and tyramine Hydrochloride. 1H
NMR (300 MHz, DMSO) δ 9.36 (s, 1H), 8.04 (s, 2H), 7.12 – 6.98 (m, 1H), 6.98 – 6.81 (m, 1H),
3.06 – 2.87 (m, 2H), 2.86 – 2.67 (m, 2H).
8.9 Hz).
Observations/Notes

19

F NMR (282 MHz, DMSO) δ -136.31 (dd, J = 12.3,
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The product of this reaction can be purified by dissolving in hot ethanol and precipitating
with ether. The product appears to contain a 60:40 mixture of fluorinated to non-fluorinated
tyramine. A more accurate analysis of the desired product is pending on separation of the
mixture by HPLC. I think that a majority of the product may have been lost because it was not
protonated and remained soluble in acetonitrile. If this reaction is perfomed again it might be a
good idea to acidify the solution with concentrated HCl before precipitating with acetonitrile.

Reference
Anal. Chem. 1998, 70, 2676-2684

(E)-4-(2-nitrovinyl)benzene-1,2-diol (17). The success of this reaction is questionable. 16
(0.250 g), AlCl3 (0.180 g) and 0.5 mL of pyridine were refluxed for 18 hours. The reaction
mixture was extracted with CHCl3, washed with H2O, dired with MgSO4 and evaporated to yield
0.200 g of a red/brown powder.13C-NMR (75 MHz, DMSO) δ 150.85 (s, J = 7.7 Hz), 146.29 (s,
J = 82.2 Hz), 140.82 (s, J = 55.6 Hz), 135.11 (s, J = 29.3 Hz), 124.20 (s, J = 56.9 Hz), 121.97 (s,
J = 62.4 Hz), 116.89 (s, J = 10.2 Hz), 116.46 (s, J = 9.2 Hz).
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1,2-Dihydroxyphenethylamine hydrochloride (Dopamine) (18). Doapmine was unable to be
synthesized from the same reaction conditions that generated 4-(2-aminoethyl)-2-fluoro-6methoxyphenol hydrochloride (11).

4-(benzyloxy)-3-methoxybenzaldehyde (20). Vanillin (1.52 g, 10 mmol), benzyl chloride (1.39
g, 11 mmol), KI (0.166 g, 1 mmol), and NaHCO3 (0.958 g, 11.4 mmol) were refluxed in 10 mL
acetonitrile for 17 hours. The solvent was removed by vacuum and 20 was extracted into ether.
The organic extract was dried using MgSO4 and evaporated to yield 2.215 g (91.5%). 1H NMR
(300 MHz, CDCl3) δ 9.91 – 9.76 (m, 1H), 7.47 – 7.32 (m, 7H), 6.99 (d, J = 8.2 Hz, 1H), 5.25 (s,
2H), 3.95 (s, 3H).

(E)-1-(benzyloxy)-2-methoxy-4-(2-nitrovinyl)benzene (21). The same procedure used to
generate (E)-2-fluoro-6-methoxy-4-(2-nitrovinyl)phenol (10) resulted in 92% yield of 21 on an 8
mmol scale. 1H NMR (300 MHz, DMSO) δ 8.23 (d, J = 13.5 Hz, 1H), 8.07 (d, J = 13.5 Hz, 1H),
7.52 (d, J = 1.9 Hz, 1H), 7.49 – 7.34 (m, 6H), 7.15 (d, J = 8.4 Hz, 1H), 5.18 (s, 2H), 3.83 (s, 3H).
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2-(4-(benzyloxy)-3-methoxyphenyl)ethanamine hydrochloride (22). 22 was unable to be
synthesized from the same reaction conditions that generated 4-(2-aminoethyl)-2-fluoro-6methoxyphenol hydrochloride (11).

4-(2-aminoethyl)-1,2-phenylene diacetate hydrochloride (24). Dopamine (18) (0.379 g, 2
mmol) and acetyl chloride (0.628 g, 8 mmol) were stirred in 8 mL TFA under nitrogen for 4.5
hours at room temperature. 1 mL of H2O was added and the volatiles were evaporated under
vacuum. The product was triturated with ether and collected on filter paper to yield 0.325 g
(60%).

1

H NMR (300 MHz, DMSO) δ 8.18 (s, 1H), 7.25 – 7.16 (m, 1H), 3.03 (dt, J = 7.7, 4.4

Hz, 1H), 2.92 (dd, J = 8.8, 5.7 Hz, 1H), 2.27 (s, 1H), 2.26 (s, 1H).
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Appendix A
NMR SPECTRA
2-Fluoro-6-methoxyphenol

(2)

46

2-Fluoro-3-hydroxy-4-methoxybenzaldehyde

(3)

47

(E)-2-fluoro-6-methoxy-3-(2-nitrovinyl)phenol

(4)

48

N,N-Dimethyl-3-hydroxy-4-methoxy-5-fluorobenzylamine

(7)

49

1-(3-fluoro-4-hydroxy-5-methoxyphenyl)-N,N,N-trimethylmethanaminium iodide

(8)

50

3-Methoxy-4-hydroxy-5-fluorobenzaldehyde

(9)

51

(E)-2-fluoro-6-methoxy-4-(2-nitrovinyl)phenol (10)

52

4-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrochloride

(11)

53

3-(2-aminoethyl)-2-fluoro-6-methoxyphenol hydrobromide (2-Fluorodopamine)

(6)
2-Fluoro-3,4-dihydroxyphenethylamine Hydrobromide (5-Flurodopamine HBr) (12)
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55
4-(aminomethyl)-2-fluorophenol hydrochloride (3-Fluorotyramine Hydrochloride)
(15)

56

(E)-4-(2-nitrovinyl)benzene-1,2-diol (17)

4-(benzyloxy)-3-methoxybenzaldehyde (20)

57

(E)-1-(benzyloxy)-2-methoxy-4-(2-nitrovinyl)benzene (21)

4-(2-aminoethyl)-1,2-phenylene diacetate hydrochloride (23)
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Appendix B
X-ray Structure Files
2-Fluoroisovanillin .res
TITL scan_0m_Pc in Pc #7
CELL 0.71073 6.36 6.8574 8.497 90 98.169 90
ZERR 2 0.0036 0.0035 0.0051 0 0.019 0
LATT -1
SYMM +X,-Y,0.5+Z

SFAC C H O F
UNIT 16 14 6 2

L.S. 100
PLAN 10 0 0
SIZE 0.19 0.2 0.2
TEMP 27
REM reset to Pc #7
BOND
fmap 2
acta
REM <HKL>C:/Users/Tom/Documents/Grad%20School/Classes/crystal%20class/work%20f
REM %20iso%20van%20the%20copy/scan_0m_Pc.hkl</HKL>

WGHT

0.059100

FVAR

0.29183

O1

3

0.079423

0.200885

0.07534 -0.00923
C2

1

0.545022

0.03118

0.291142 -0.010556

11.00000

0.05204

0.03147 =

0.05036

0.03337 =

0.00000

0.426422

11.00000

59
0.05346
O3

3

0.00202

0.02045 -0.00686

0.179643 -0.166551

0.08105 -0.00746

0.467885

11.00000

0.06527

0.02936 =

0.04567 -0.00366

AFIX 147
H3

2

0.096600 -0.131088

0.527671

11.00000 -1.50000

0.245724

0.463481

11.00000

AFIX 0
C4

1

0.179331

0.04068 -0.00237
C5

1

0.461030 -0.042868

0.04641 -0.00444
F

4

1

0.364416

11.00000

0.04447

0.03180 =

0.00461

0.313492

11.00000

0.06706

0.02588 =

0.04650

0.01942 =

0.04283 -0.00020

0.333471

0.06798 -0.00200

0.03630 =

0.00841

0.345805

0.01452

0.507846 -0.229445

0.08786 -0.00417
C8

0.01363

0.03916

0.414082

11.00000

0.01762 -0.00567

AFIX 43
H8

2

0.331576

0.461348

0.437733

11.00000 -1.20000

0.583153

0.105417

0.294325

11.00000

AFIX 0
C12 1

0.04959 -0.00121
C14 1

0.529854

0.05487

0.03306 =

0.04580

0.03303 =

0.00890 -0.00226

0.295763

0.00623

0.04145

0.330443

11.00000

0.01956 -0.00744

AFIX 43
H14 2

0.607548

0.399130

0.297395

11.00000 -1.20000

AFIX 0
O

3

0.867962

0.08468
C

1

0.189154

0.00188

0.755812

11.00000

0.06142

0.04110 =

0.05123

0.04234 =

0.03622 -0.01058

0.065877

0.06161 -0.00125

0.155311

0.203889

0.02301

11.00000

0.00555

AFIX 43
H

2

0.782622 -0.063748

0.181421

11.00000 -1.20000

60
AFIX 0
C0AA 1

0.017013

0.394399

0.08051 -0.01199

0.582324

0.03617

11.00000

0.06375

0.03763 =

0.00978

AFIX 137
H0AA 2 -0.018934

0.467346

0.485821

11.00000 -1.50000

H0AC 2

0.132301

0.457431

0.648261

11.00000 -1.50000

H0AB 2 -0.104123

0.388022

0.637873

11.00000 -1.50000

HKLF 4

REM scan_0m_Pc in Pc #7
REM R1 = 0.0622 for
REM

835 Fo > 4sig(Fo) and 0.0791 for all 1054 data

111 parameters refined using

2 restraints

END

WGHT

0.0589

0.0000

REM Highest difference peak 0.245, deepest hole -0.234, 1-sigma level 0.058
Q1

1 1.0536 0.2157 0.2846 11.00000 0.05

0.25

Q2

1 0.3814 -0.2044 0.1691 11.00000 0.05

0.23

Q3

1 0.7308 0.1796 -0.0124 11.00000 0.05

0.22

Q4

1 0.7534 0.2133 0.0324 11.00000 0.05

0.22

Q5

1 0.6518 -0.2037 0.4636 11.00000 0.05

0.19

Q6

1 0.2894 -0.1640 0.6133 11.00000 0.05

0.19

Q7

1 0.1759 0.2047 0.6631 11.00000 0.05

0.18

Q8

1 0.1276 -0.2134 0.3168 11.00000 0.05

0.18

Q9

1 0.4971 0.0252 0.1237 11.00000 0.05

0.17

Q10 1 0.4721 0.1502 0.1736 11.00000 0.05

0.16
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5-Fluorodopamine.res
TITL scan_0m_p21_c in P21/c #14
CELL 0.71073 10.8217 12.8844 6.8447 90 92.384 90
ZERR 4 0.0032 0.0033 0.0023 0 0.01 0
LATT 1
SYMM -X,0.5+Y,0.5-Z

SFAC C H N O F Br
UNIT 32 24 4 8 4 4

L.S. 20
SIZE 0.08 0.48 0.65
TEMP 27
REM reset to P21/c #14
BOND
fmap 2
acta
OMIT -5 5 7
OMIT 4 2 7
OMIT 3 2 7
OMIT 5 2 7
OMIT -4 1 7
REM <HKL>C:/Users/Tom/Desktop/crystal%20structure/Fluoro%20dopamine%20crystal/
REM scan_0m_P21_c.hkl</HKL>

WGHT

0.196300

FVAR

0.10641

BR1 6

0.472600

0.05684

0.120548

0.00030

0.237025

0.00420

0.00002

11.00000

0.03365

0.02904 =

62
F

5

0.192245 -0.363433

0.10399 -0.00466
O0AA 4

0.293668

0.00484

0.322844 -0.181782

0.10142 -0.00558

11.00000

0.02918 =

0.01172
0.247179

0.00429

0.04002

11.00000

0.02560

0.03389 =

0.00082

AFIX 147
H0A 2

0.347079 -0.241617

0.234624

11.00000 -1.50000

AFIX 0
O

4

0.192770

0.002580

0.14008 -0.00149

0.247882

11.00000

0.03276

0.02324 =

0.01123 -0.00739

AFIX 147
H

2

0.259763 -0.008462

0.200124

11.00000 -1.50000

0.325150

11.00000

AFIX 0
C4

1 -0.058910 -0.179691
0.04045

N

0.00235

0.00537

0.03306 =

0.02607

0.04082 =

0.00487 -0.00274

3 -0.406029 -0.117787
0.06601

0.03847

0.277495

0.00536

11.00000

0.00462

AFIX 137
HA 2 -0.448280 -0.068955

0.211446

11.00000 -1.50000

HC

2 -0.422494 -0.113884

0.403599

11.00000 -1.50000

HB

2 -0.427923 -0.180013

0.231438

11.00000 -1.50000

AFIX 0
C6

1

0.129128 -0.270515

0.04644 -0.00064
C7

1

0.00604

0.003986 -0.272919

0.05358

0.00139

0.296916

11.00000

0.04374

0.02933 =

0.03884

0.02574 =

0.00604

0.322137

11.00000

0.00030 -0.00404

AFIX 43
H7

2 -0.037295 -0.335568

0.336786

11.00000 -1.20000

0.271942

11.00000

AFIX 0
C8

1

0.132118 -0.089614

0.05491 -0.00472

0.00184 -0.00811

0.03882

0.03211 =

63
C9

1

0.006020 -0.087615

0.07481 -0.00065

0.298486

0.00338

11.00000

0.03722

0.02620 =

0.00157

AFIX 43
H9

2 -0.035650 -0.024488

0.298538

11.00000 -1.20000

0.273390

11.00000

0.02151

0.02972 =

11.00000

0.02899

0.04701 =

AFIX 0
C10 1

0.197402 -0.181978

0.05289

0.00055

0.00189

C11 1 -0.270647 -0.101847
0.05546

0.01188

0.00209

0.253984

0.00546 -0.00746

AFIX 23
H11B 2 -0.247981 -0.032561

0.297795

11.00000 -1.20000

H11A 2 -0.252847 -0.107243

0.116629

11.00000 -1.20000

AFIX 0
C12 1 -0.194433 -0.179853
0.05367

0.00507

0.368024

11.00000

0.03277

0.04025 =

0.00428 -0.00129

AFIX 23
H12B 2 -0.227641 -0.248491

0.340584

11.00000 -1.20000

H12A 2 -0.202644 -0.166549

0.506365

11.00000 -1.20000

HKLF 4

REM scan_0m_p21_c in P21/c #14
REM R1 = 0.0922 for 1321 Fo > 4sig(Fo) and 0.1067 for all 1684 data
REM

121 parameters refined using

0 restraints

END

WGHT

0.1963

0.0000

REM Highest difference peak 4.397, deepest hole -0.931, 1-sigma level 0.242
Q1

1 0.4742 0.1221 0.3887 11.00000 0.05

4.40

Q2

1 0.4701 0.1226 0.0951 11.00000 0.05

3.14

64
Q3

1 0.0054 -0.2658 0.1556 11.00000 0.05

0.94

Q4

1 -0.2002 -0.1830 0.1516 11.00000 0.05

0.94

Q5

1 -0.0562 -0.1805 0.1763 11.00000 0.05

0.91

Q6

1 -0.4153 -0.1209 0.1340 11.00000 0.05

0.83

Q7

1 -0.3838 -0.1166 0.0278 11.00000 0.05

0.82

Q8

1 0.1911 -0.3608 0.1366 11.00000 0.05

0.81

Q9

1 -0.2004 -0.1820 0.0130 11.00000 0.05

0.75

Q10 1 0.3187 -0.1838 0.3857 11.00000 0.05

0.65

Q11 1 0.1337 -0.2653 0.1471 11.00000 0.05

0.64

Q12 1 0.5599 0.1211 0.2043 11.00000 0.05

0.60

Q13 1 0.1908 -0.1871 0.1282 11.00000 0.05

0.58

Q14 1 0.1841 0.0014 0.4088 11.00000 0.05

0.57

Q15 1 0.0023 -0.0837 0.1349 11.00000 0.05

0.57

Q16 1 0.1779 0.0086 0.0635 11.00000 0.05

0.46

Q17 1 0.3169 0.1209 0.2386 11.00000 0.05

0.46

Q18 1 0.0681 -0.2587 0.3701 11.00000 0.05

0.45

Q19 1 -0.2549 -0.3676 0.3632 11.00000 0.05

0.45

Q20 1 -0.5951 -0.0730 0.1606 11.00000 0.05

0.43
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